Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies... Show more
Precision BioSciences is a clinical-stage gene editing company, meaning its quarterly results are driven less by revenue than by progress in its pipeline and its ability to preserve cash. The company is advancing two wholly owned programs built on its ARCUS genome editing platform: PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy. With no approved products generating commercial sales, investors watch quarterly updates primarily for clinical milestones, spending discipline, and cash runway. The third-quarter report matters because it shows whether the company is staying on schedule toward data readouts while maintaining a balance sheet that can fund expensive trials without near-term dilution.
For the third quarter ended September 30, 2026, Precision BioSciences reported a net loss of $7.6 million, or $(0.28) per share (basic and diluted), compared with a net loss of $21.8 million, or $(1.84) per share, in the same period a year earlier. The loss per share came in ahead of the consensus estimate of roughly $(0.84). The improvement was largely attributable to $12.8 million in other income, primarily a non-cash gain from a change in the fair value of the company's warrant liability, which does not affect operating cash runway.
Revenue was zero for the quarter, compared with less than $0.1 million a year earlier, when revenue was recognized from a prior Novartis agreement. Research and development (R&D) expenses were $12.7 million, down from $13.4 million a year ago, while general and administrative (G&A) expenses rose slightly to $7.7 million from $7.3 million. The company reported approximately $108.0 million in cash, cash equivalents, and restricted cash as of September 30, 2026.
Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Whether you are tracking a clinical-stage biotech like Precision BioSciences or scanning the broader healthcare sector, the AI Screener can help you identify candidates that match your criteria.
Because Precision BioSciences is pre-revenue, market reaction around its earnings tends to hinge on the clinical narrative and cash position rather than headline sales figures. A narrower-than-expected loss and an extended cash runway are generally viewed favorably, but the absence of revenue and the reminder that a meaningful portion of the improvement stemmed from a non-cash warrant adjustment may temper enthusiasm. Investors are also weighing the significance of clinical progress, including the first patient dosed in the PBGENE-DMD study, against the inherent risk that trial readouts could fall short of expectations. Sentiment heading into the report was focused on whether the company could maintain momentum toward year-end data updates.
Looking ahead, the key drivers for Precision BioSciences are clinical data, not quarterly revenue. Management indicated it remains on track to deliver data updates from both the PBGENE-HBV and PBGENE-DMD programs by year-end. A late-breaking oral presentation for the ELIMINATE-B trial in chronic hepatitis B is scheduled for November 8 at The Liver Meeting 2026, with the data abstract due for release November 5.
Investors should watch for evidence of sustained viral response in the hepatitis B program, as well as early safety and activity signals from the Duchenne muscular dystrophy study, where the first patient has now been dosed. Cash runway through 2028 reduces near-term financing risk, but the company remains dependent on capital markets and its at-the-market facility if timelines shift.
Cost discipline will also remain in focus. R&D spending declined year over year, and continued expense control will determine how far the existing cash balance can stretch. As a clinical-stage biotech, Precision BioSciences remains exposed to binary outcomes tied to trial results, so any positive or negative data readout is likely to have an outsized impact on the stock relative to the company's modest revenue base.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
a developer of technology to produce custom, genome-editing enzymes for human health and biological research
Industry Biotechnology